Related Experiment Video
Updated: Aug 13, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
Small Molecule Inhibitors for Unc-51-like Autophagy-Activating Kinase Targeting Autophagy in Cancer
Ujjwala Karmacharya1,2, Jong-Wha Jung1,2
1College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea.
Abstract:
Autophagy is a cellular process that removes damaged components of cells and recycles them as biochemical building blocks. Autophagy can also be induced to protect cells in response to intra- and extracellular stresses, including damage to cellular components, nutrient deprivation, hypoxia, and pathogenic invasion. Dysregulation of autophagy has been attributed to various diseases. In particular, autophagy protects cancer cells by supporting tumor cell survival and the development of drug resistance. Understanding the pathophysiological mechanisms of autophagy in cancer has stimulated the research on discovery and development of specific inhibitors targeting various stages of autophagy. In recent years, Unc-51-like autophagy-activating kinase (ULK) inhibitors have become an attractive strategy to treat cancer. This review summarizes recent discoveries and developments in small-molecule ULK inhibitors and their potential as anticancer agents. We focused on structural features, interactions with binding sites, and biological effects of these inhibitors. Overall, this review will provide guidance for using ULK inhibitors as chemical probes for autophagy in various cancers and developing improved ULK inhibitors that would enhance therapeutic benefits in the clinic.
Insights
Autophagy, a cellular recycling process, is crucial in cancer. Unc-51-like autophagy-activating kinase (ULK) inhibitors show promise as anticancer agents by targeting this pathway.
Area of Science:
- Cell Biology
- Molecular Biology
- Oncology
Background:
- Autophagy is a fundamental cellular process for degrading and recycling damaged components, crucial for cellular homeostasis.
- Dysregulation of autophagy is implicated in various diseases, notably cancer, where it promotes tumor survival and drug resistance.
Purpose of the Study:
- To review recent advancements in small-molecule Unc-51-like autophagy-activating kinase (ULK) inhibitors.
- To explore the potential of ULK inhibitors as anticancer agents by examining their structural features, binding interactions, and biological effects.
Main Methods:
- Literature review of recent discoveries and developments in ULK inhibitors.
- Analysis of structural characteristics, binding site interactions, and biological activities of small-molecule ULK inhibitors.
Main Results:
- ULK inhibitors represent a promising strategy for cancer therapy by targeting the autophagy pathway.
- Detailed understanding of ULK inhibitor mechanisms can guide their use as chemical probes and inform the development of improved therapeutic agents.
Conclusions:
- ULK inhibitors are emerging as valuable tools for cancer research and treatment.
- Further development of ULK inhibitors could lead to enhanced therapeutic benefits in clinical oncology.
Related Concept Videos
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...

